

Ambit Biosciences Corp

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 01-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 12

[Return to Table of Contents](#)

Ambit Biosciences Corp

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | Ambit Biosciences Corp |
| Parent Company Name | Ambit Biosciences Corp |
| Website | http://www.ambitbio.com/ |
| Country | US |
| Number of Drugs in Active Development | 3 |
| Number of Inactive Drugs | 11 |
| Number of Patents as Owner | 41 |
| Number of Patents as Third Party | 1 |
| Number of Deals | 10 |
| Key Indications | Cancer, Inflammatory disease, Autoimmune disease, Acute myelogenous leukemia, Breast tumor, Leukemia, Insulin dependent diabetes, Multiple sclerosis, Myeloproliferative disorder, Solid tumor |
| Key Target-based Actions | CSF-1 antagonist, Jak2 tyrosine kinase inhibitor, Flt3 tyrosine kinase inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Aurora protein kinase 2 inhibitor, ErbB4 tyrosine kinase receptor inhibitor, ABL family tyrosine kinase inhibitor, Protein kinase inhibitor, Raf B protein kinase inhibitor, VEGF-2 receptor antagonist |
| Key Technologies | Small molecule therapeutic, Oral formulation, Oral liquid formulation, Crystalline form, Salt synthesis, Antibody, Drug combination, Drug screening, Fluorescence, Formulation preservation, Intravenous formulation |

COMPANY PROFILE

SUMMARY

Ambit Biosciences, based in San Diego, CA is a privately held biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for cancer and other diseases. The company identifies and manufactures these molecules using its kinase profiling platform technology, KinomeScan.

COMPANY LOCATION

The company is based in San Diego, CA. It also has a research facility based in Toronto, Canada.

LICENSING AGREEMENTS

In November 2006, Ambit agreed to screen, discover and develop kinase inhibitors with Cephalon using its KinomeScan technology and Cephalon's kinase libraries. Cephalon would pay Ambit \$18 million upfront and make milestone payments up to \$232.5 million plus royalties. The companies also planned to advance two programs targeting undisclosed kinases.

In December 2005, Ambit and Bristol-Myers Squibb (BMS) expanded their collaboration to discover kinase inhibitors. The new, 5-year agreement provided BMS with access to Ambit's kinase profiling technology, KinomeScan, to accelerate its internal drug discovery and development efforts. Ambit received a license to a BMS preclinical kinase inhibitor program for the treatment of solid tumors. Ambit would also get an upfront payment, equity investment and profiling revenue from BMS. In January 2004, Ambit entered into separate kinase screening collaborations with Bristol-Myers Squibb Co and GlaxoSmithKline plc, whereby Ambit would employ its kinase platform to characterize the specificity of certain compounds from the companies' compound libraries. Ambit also entered into a compound profiling agreement with Pfizer Inc's La Jolla Laboratories. Ambit would employ its Reverse Screening technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds and therefore elucidate their molecular mechanisms of actions.

In August 2004, Roche Holding AG and Ambit entered into a multiyear collaboration. Roche would use Ambit's kinase screening platform to profile and select small-molecule kinase inhibitors. Ambit would receive milestone payments and royalties on drugs developed through the collaboration.

[Return to Table of Contents](#)



In March 2003, Ambit signed a technology evaluation agreement with GlaxoSmithKline (GSK) to characterize small molecule kinase inhibitors using Ambit's ProteomeScan platform.

In April 2002, Ambit entered into a research collaboration agreement with AstraZeneca Pharmaceuticals LP (AZ), whereby AZ was to utilize Ambit's ProteomeScan platform to identify and isolate the protein targets of its portfolio of small molecules.

In November 2001, Medarex Inc and Ambit entered into a multiyear strategic collaboration to jointly develop and commercialize therapeutic monoclonal antibodies, utilizing Medarex's UltiMAb human antibody development system and Ambit's ProteomeScan screening technology. Both companies expected to share equally the costs and revenues associated with the preclinical and clinical development and subsequent commercialization of any resulting products. Additionally, Medarex made a \$1 million equity investment in Ambit.

The company was founded to commercialize technology initially developed in Dr Austin's laboratory in the Chemistry Department at Yale University. This technology, called ProteomeScan, has been exclusively licensed by Ambit Biosciences from Yale University and is the subject of pending US and international patent applications.

FINANCIAL

In May 2013, Ambit priced its initial public offering of 8,125,000 shares of its common stock at \$8 per share. Underwriters were granted a 30-day option to purchase an additional 1,218,750 shares. The common stock began trading on the NASDAQ Global Market under the symbol "AMBI".

In February 2013, Ambit filed a registration (form S-1) for an initial public common stock offering on the NASDAQ market.

In November 2012, Ambit raised \$25 million in the first tranche of a new \$50 million stock financing round.

In June 2011, Ambit raised \$30 million from a series D-2 equity financing round.

In November 2010, Ambit filed a registration statement for an IPO with the SEC. Later that month, the IPO was reported to be expected to raise \$86.3 million.

In November 2007, Ambit raised \$49.3 million from a series D equity financing round. Ambit would use the proceeds to advance its pipeline products.

In May 2005, Ambit closed a series C financing, led by Roche, raising a total of \$31 million. The first \$21 million tranche was secured in August 2004.

The company raised \$10 million in November 2001.

In November 2000, Ambit raised \$18.8 million from a series B financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Neoplasm | 3 | 10 | 13 |
| Inflammatory disease | 2 | 2 | 4 |
| Immune disorder | 1 | 1 | 2 |
| Neurological disease | 0 | 2 | 2 |
| Hematological disease | 1 | 1 | 2 |
| Musculoskeletal disease | 0 | 1 | 1 |
| Cardiovascular disease | 0 | 1 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 2 Clinical | 1 |
| Phase 1 Clinical | 1 |
| Discovery | 1 |
| Discontinued | 3 |
| No Development Reported | 8 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 1 | 0 | 0 | 0 | 1 |
| Drug - Screening/Evaluation | 5 | 0 | 0 | 0 | 5 |
| Drug - Early Research/Development | 1 | 0 | 1 | 0 | 2 |
| Drug - Development/Commercialization License | 1 | 0 | 1 | 0 | 2 |

[Return to Table of Contents](#)



CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|-------------------------|---------|-----|
| Neoplasm | 6 | 10 |
| Hematological disease | 4 | 6 |
| Immune disorder | 0 | 2 |
| Inflammatory disease | 0 | 1 |
| Musculoskeletal disease | 0 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 2 | 2 |
| Phase 1 | 4 | 9 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease | 8 | 1 | 9 |
| Endocrine disease | 16 | 1 | 17 |
| Gastrointestinal disease | 14 | 1 | 15 |
| Genitourinary disease | 11 | 0 | 11 |
| Growth disorder | 2 | 0 | 2 |
| Hematological disease | 24 | 1 | 25 |
| Degeneration | 3 | 0 | 3 |
| Andrology | 2 | 0 | 2 |
| Immune disorder | 24 | 1 | 25 |
| Psychiatric disorder | 1 | 0 | 1 |

[Return to Table of Contents](#)



| | | | |
|--------------------------------|----|---|----|
| Musculoskeletal disease | 7 | 0 | 7 |
| Neoplasm | 36 | 1 | 37 |
| Ocular disease | 5 | 0 | 5 |
| Genetic disorder | 2 | 0 | 2 |
| Metabolic disorder | 11 | 1 | 12 |
| Neurological disease | 14 | 1 | 15 |
| Nutritional disorder | 1 | 0 | 1 |
| Respiratory disease | 11 | 0 | 11 |
| Infectious disease | 4 | 0 | 4 |
| Unidentified indication | 2 | 0 | 2 |
| Inflammatory disease | 27 | 0 | 27 |
| Otorhinolaryngological disease | 2 | 0 | 2 |
| Gynecology and obstetrics | 10 | 0 | 10 |
| Dermatological disease | 8 | 0 | 8 |
| Surgical procedure | 0 | 1 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

quizartinib dihydrochloride

| | |
|-----------------------------|---|
| Drug Name | quizartinib dihydrochloride |
| Key Synonyms | quizartinib dihydrochloride, quizartinib |
| Originator Company | Ambit Biosciences Corp |
| Active Companies | Ambit Biosciences Corp |
| Inactive Companies | Astellas Pharma Inc |
| Highest Status | Phase 2 Clinical |
| Active Indications | Acute myelogenous leukemia |
| Target-based Actions | Flt3 tyrosine kinase inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist |
| Other Actions | Apoptosis stimulator, Anticancer protein kinase inhibitor |
| Technologies | Oral formulation, Oral liquid formulation, Small molecule therapeutic |
| Last Change Date | 14-May-2013 |

AC-410

| | |
|-----------------------------|--|
| Drug Name | AC-410 |
| Key Synonyms | |
| Originator Company | Ambit Biosciences Corp |
| Active Companies | Ambit Biosciences Corp |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Cancer, Inflammatory disease, Autoimmune disease |
| Target-based Actions | Jak2 tyrosine kinase inhibitor |
| Other Actions | Anticancer protein kinase inhibitor, Anti-inflammatory |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 26-Feb-2013 |

[Return to Table of Contents](#)

AC-708

| | |
|-----------------------------|--|
| Drug Name | AC-708 |
| Key Synonyms | |
| Originator Company | Ambit Biosciences Corp |
| Active Companies | Ambit Biosciences Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer, Inflammatory disease |
| Target-based Actions | CSF-1 antagonist |
| Other Actions | Anticancer protein kinase inhibitor, Bone modulator, Anti-inflammatory |
| Technologies | Small molecule therapeutic |
| Last Change Date | 24-May-2013 |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)